Methotrexate Treatment Causes Early Onset of Disease in a Mouse Model of Ross River Virus-Induced Inflammatory Disease through Increased Monocyte Production

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Taylor, Adam ^a   Sheng, Kuo Ching ^a   Herrero, Lara J ^a   Chen, Weiqiang ^a   Rulli, Nestor E ^a   Mahalingam, Suresh ^a  

^a GRIFFITH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CYTOKINE; METHOTREXATE; PLACEBO;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CELL MIGRATION; CONTROLLED STUDY; DRUG EFFECT; HISTOPATHOLOGY; INFLAMMATORY CELL; INFLAMMATORY DISEASE; MONOCYTE; MOUSE; MUSCLE TISSUE; MUSCULOSKELETAL DISEASE; NONHUMAN; PATHOGENESIS; QUADRICEPS FEMORIS MUSCLE; ROSS RIVER ALPHA VIRUS; SKELETAL MUSCLE; TOGAVIRUS INFECTION; VIRUS LOAD;

ALPHAVIRUS INFECTIONS; ANIMALS; ANTIGENS, CD11B; ANTIRHEUMATIC AGENTS; ARTHRITIS; DISEASE MODELS, ANIMAL; INFLAMMATION; INFLAMMATION MEDIATORS; METHOTREXATE; MICE; MONOCYTES; MUSCLE, SKELETAL; ROSS RIVER VIRUS;

EID: 84881526160     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0071146     Document Type: Article

References (30)

1. Slaon-Gardner T, Stirzaker S, Knuckey D, Pennington K, Knope K, et al. (2011) Australia's notifiable disease status, 2009: annual report of the National Notifiable Diseases Surveillance System. Commun Dis Intell Q Rep 35: 61-131.
2. Government WA (2012) Ross River virus notifications in Western Australia; January 2008 to March 2012. Department of Health. Accessed 6 Apri 2012. Available: http://www.public.health.wa.gov.au/3/1528/3/ross_river_virus.pm.
3. Kline K, McCarthy JS, Pearson M, Loukas A, Hotez PJ, (2013) Neglected tropical diseases of oceania: review of their prevalence, distribution, and opportunities for control. PLoS Negl Trop Dis 7: e1755.
4. Harley D, Sleigh A, Ritchie S, (2001) Ross River virus transmission, infection, and disease: a cross-disciplinary review. Clin Microbiol Rev 14: 909-932.
5. Soden M, Vasudevan H, Roberts B, Coelen R, Hamlin G, et al. (2000) Detection of viral ribonucleic acid and histologic analysis of inflamed synovium in Ross River virus infection. Arthritis Rheum 43: 365-369.
6. Hoarau JJ, Jaffar Bandjee MC, Krejbich Trotot P, Das T, Li-Pat-Yuen G, et al. (2010) Persistent chronic inflammation and infection by Chikungunya arthritogenic alphavirus in spite of a robust host immune response. J Immunol 184: 5914-5927.
7. Lidbury BA, Rulli NE, Suhrbier A, Smith PN, McColl SR, et al. (2008) Macrophage-derived proinflammatory factors contribute to the development of arthritis and myositis after infection with an arthrogenic alphavirus. J Infect Dis 197: 1585-1593.
8. Gardner J, Anraku I, Le TT, Larcher T, Major L, et al. (2010) Chikungunya virus arthritis in adult wild-type mice. J Virol 84: 8021-8032.
9. Suhrbier A, La Linn M, (2004) Clinical and pathologic aspects of arthritis due to Ross River virus and other alphaviruses. Current Opinion in Rheumatology 16: 374-379.
10. Weinblatt ME, Weissman BN, Holdsworth DE, Fraser PA, Maier AL, et al. (1992) Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis. 84-month update. Arthritis Rheum 35: 129-137.
11. Kuhn RJ, Niesters HG, Hong Z, Strauss JH, (1991) Infectious RNA transcripts from Ross River virus cDNA clones and the construction and characterization of defined chimeras with Sindbis virus. Virology 182: 430-441.
12. Rulli NE, Guglielmotti A, Mangano G, Rolph MS, Apicella C, et al. (2009) Amelioration of alphavirus-induced arthritis and myositis in a mouse model by treatment with bindarit, an inhibitor of monocyte chemotactic proteins. Arthritis Rheum 60: 2513-2523.
13. Swirski FK, Nahrendorf M, Etzrodt M, Wildgruber M, Cortez-Retamozo V, et al. (2009) Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science 325: 612-616.
14. Chopra A, Anuradha V, Lagoo-Joshi V, Kunjir V, Salvi S, et al. (2008) Chikungunya virus aches and pains: an emerging challenge. Arthritis Rheum 58: 2921-2922.
15. Allegra CJ, Drake JC, Jolivet J, Chabner BA, (1985) Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates. Proc Natl Acad Sci U S A 82: 4881-4885.
16. Kremer JM, Galivan J, Streckfuss A, Kamen B, (1986) Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients. Association with hepatic folate deficiency and formation of polyglutamates. Arthritis Rheum 29: 832-835.
17. Kimura E, Nishimura K, Sakata K, Oga S, Kashiwagi K, et al. (2004) Methotrexate differentially affects growth of suspension and adherent cells. Int J Biochem Cell Biol 36: 814-825.
18. Freeman-Narrod M, Narrod SA, (1977) Chronic toxicity of methotrexate in mice. J Natl Cancer Inst 58: 735-741.
19. Morrison TE, Whitmore AC, Shabman RS, Lidbury BA, Mahalingam S, et al. (2006) Characterization of Ross River virus tropism and virus-induced inflammation in a mouse model of viral arthritis and myositis. J Virol 80: 737-749.
20. Cronstein BN, Naime D, Ostad E, (1993) The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest 92: 2675-2682.
21. Chan ES, Cronstein BN, (2010) Methotrexate-how does it really work? Nat Rev Rheumatol 6: 175-178.
22. Johnston A, Gudjonsson JE, Sigmundsdottir H, Ludviksson BR, Valdimarsson H, (2005) The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules. Clin Immunol 114: 154-163.
23. Seitz M, Zwicker M, Loetscher P, (1998) Effects of methotrexate on differentiation of monocytes and production of cytokine inhibitors by monocytes. Arthritis Rheum 41: 2032-2038.
24. Rulli NE, Rolph MS, Srikiatkhachorn A, Anantapreecha S, Guglielmotti A, et al. (2011) Protection from arthritis and myositis in a mouse model of acute chikungunya virus disease by bindarit, an inhibitor of monocyte chemotactic protein-1 synthesis. J Infect Dis 204: 1026-1030.
25. Zaid A, Rulli NE, Rolph MS, Suhrbier A, Mahalingam S, (2011) Disease exacerbation by etanercept in a mouse model of alphaviral arthritis and myositis. Arthritis Rheum 63: 488-491.
26. McLean-Tooke A, Aldridge C, Waugh S, Spickett GP, Kay L, (2009) Methotrexate, rheumatoid arthritis and infection risk: what is the evidence? Rheumatology (Oxford) 48: 867-871.
27. Bernatsky S, Hudson M, Suissa S, (2007) Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis. Rheumatology (Oxford) 46: 1157-1160.
28. Smitten AL, Choi HK, Hochberg MC, Suissa S, Simon TA, et al. (2008) The risk of hospitalized infection in patients with rheumatoid arthritis. J Rheumatol 35: 387-393.
29. Boerbooms AM, Kerstens PJ, van Loenhout JW, Mulder J, van de Putte LB, (1995) Infections during low-dose methotrexate treatment in rheumatoid arthritis. Semin Arthritis Rheum 24: 411-421.
30. LeMense GP, Sahn SA, (1994) Opportunistic infection during treatment with low dose methotrexate. Am J Respir Crit Care Med 150: 258-260.